SUBSCRIBE
SUBSCRIBE

RayzeBio

RayzeBio is a dynamic biotechnology company headquartered in San Diego, CA. Launched in late 2020 and recently acquired by Bristol Myers Squibb (BMS) as a wholly owned subsidiary, the company is focused on improving survival of people with cancer by harnessing the power of targeted radioisotopes. RayzeBio operates as a standalone entity within the BMS organization, maintaining its biotech culture with the opportunity to leverage the best-in-class oncology capabilities of BMS. RayzeBio is developing innovative drugs against targets of solid tumors. The lead asset, RYZ101, is in Phase 3 testing for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs), as well as earlier stage testing for patients with small cell lung cancer (SCLC). Led by a successful and experienced entrepreneurial team, RayzeBio aims to be the global leader in radiopharmaceuticals.

5505 Morehouse Drive, Suite 300
San Diego CA 92121
Tel: 8582573421
Visit website
Email Us
NEWS
Self-knowledge, exploration of own soul, psyche, illumination of hidden in shadow.
Radiopharma
Novartis Drops Up to $745M to Move Deeper Into Competitive Radiopharma Space
The deal has secured Novartis the chance to work with Ratio Therapeutics on a novel drug candidate that could fortify the Big Pharma against competition from would-be radiopharmaceutical rivals such as BMS and Lilly.
November 18, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Abstract handshake
Deals
7 Billion-Dollar Oncology M&As from Q1
AbbVie’s $10.1 billion takeover of ImmunoGen paces the cancer sector in early 2024, as ADCs and radiopharmaceuticals remain hot.
April 9, 2024
 · 
4 min read
 · 
Neil Versel
Pictured: Businessmen shaking hands after closing a deal
Deals
Biopharma Closes 2023 with Flurry of M&A Activity from AstraZeneca, BMS, Roche
All three companies closed out the year, which saw significant growth in mergers and acquisitions, with high-value deals that could potentially set the tone for M&A in 2024.
January 2, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Series of outcroppings with steep cliffs
Drug Development
Biotech Financing, IPO Tide May Be Turning – Signs of a Potential Recovery?
In the largest biotech Series C financing so far this year, Generate:Biomedicines raised $273 million, while Neumora and RayzeBio announced IPO pricing valued at more than $560 million combined.
September 15, 2023
 · 
2 min read
 · 
Greg Slabodkin
Pictured: Nasdaq signage and building in New York City
Deals
RayzeBio’s $311M, Neumora’s $250M IPOs Among Biotech’s Largest This Year
The two biotech companies announced initial public offering pricing Thursday, respectively, with shares beginning trading Friday and valued at more than $560 million cumulatively.
September 15, 2023
 · 
2 min read
 · 
Kate Goodwin
male hands with wrist watch is considered American dollars. Hands holding dollar cash. 1000 dollars in 100 bills in a man's hand close-up on a dark background. hundred
Business
Money on the Move: Sparing Vision, RayzeBio, Nimbus and More Garner Funds
This week was rife with Series financings, which channeled money into innovative treatments for immune diseases and cancers, genomic treatments and precision healthcare.
September 14, 2022
 · 
5 min read
 · 
Tristan Manalac
Business
RayzeBio-Partnered Startup Focused on Bringing Radiopharmaceuticals to China
Ablaze has aligned itself with RayzeBio, giving Ablaze a solid start with an in-licensing agreement to bring Rayze’s products to the greater China market.
November 30, 2021
 · 
2 min read
 · 
Kate Goodwin
JOBS
IN THE PRESS
Deals
Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform
February 26, 2024
 · 
5 min read
Deals
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
February 12, 2024
 · 
6 min read
Deals
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
December 26, 2023
 · 
15 min read
Business
RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023
 · 
8 min read
Biotech Beach
RayzeBio to Participate in Upcoming Investor Conferences in November 2023
November 6, 2023
 · 
1 min read
Business
RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors
November 1, 2023
 · 
4 min read
Policy
FDA selects RayzeBio to Participate in the Inaugural CDRP Program to Expedite Commercial Manufacturing Readiness for RYZ101 in GEP-NETs
October 24, 2023
 · 
5 min read
Biotech Beach
RayzeBio to Present at European Society for Medical Oncology (ESMO) Congress
October 18, 2023
 · 
4 min read
Deals
RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 19, 2023
 · 
3 min read
Deals
RayzeBio, Inc. Announces Pricing of Upsized $311 Million Initial Public Offering
September 14, 2023
 · 
3 min read
Load More